Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Noncash Merger Related Costs

1.9 / 5 stars · 34/88 Roast Me

AKEBIA THERAPEUTICS, INC. Noncash Merger Related Costs

AKEBIA THERAPEUTICS, INC. (AKBA) reported Noncash Merger Related Costs of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.

Discontinued › Cash Flow › Operating Activities

us-gaap:NoncashMergerRelatedCosts · last filed 2021-02-25

  • AKEBIA THERAPEUTICS, INC. noncash merger related costs for fiscal 2020 was $0.00.
  • AKEBIA THERAPEUTICS, INC. noncash merger related costs for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
  • AKEBIA THERAPEUTICS, INC. noncash merger related costs for fiscal 2018 was $13.39M.
Period endNoncash Merger Related Costs 12 month
2020-12-31$0.00
10-K · filed 2021-02-25
2019-12-31$0.00
10-K · filed 2021-02-25
2018-12-31$13.39M
10-K · filed 2021-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33